On the other side, combinations including the novel mAbs, such as PD-1_1 or PD-L1_1 with ID1 [27,28], not only showed a more potent cancer cell killing activity in co-cultures of tumor cells and hPBMCs, inducing about 50% and 40% of cells lysis, respectively, associated with secretion of higher levels of IL-2 and IFN-γ, but proved also to be lower cardiotoxic than the Nivolumab–Ipilimumab combination in co-cultures of cardiomyocytes and lymphocytes showing reduced cell lysis and lower levels of IL-6 pro-inflammatory cytokine. This evidence concerns the gene IL2 and cancer.